4//SEC Filing
Zanganeh Mahkam 4
Accession 0001599298-25-000091
CIK 0001599298other
Filed
Apr 30, 8:00 PM ET
Accepted
May 1, 6:03 PM ET
Size
9.9 KB
Accession
0001599298-25-000091
Insider Transaction Report
Form 4
Zanganeh Mahkam
DirectorCo-Chief Executive Officer10% Owner
Transactions
- Award
Stock Option (right to buy)
2025-04-29+1,040,000→ 1,040,000 totalExercise: $1.06Exp: 2032-06-28→ Common Stock (1,040,000 underlying) - Award
Stock Option (right to buy)
2025-04-29+9,590,558→ 9,590,558 totalExercise: $1.68Exp: 2033-10-13→ Common Stock (9,590,558 underlying) - Award
Stock Option (right to buy)
2025-04-29+400,000→ 400,000 totalExercise: $1.29Exp: 2032-09-09→ Common Stock (400,000 underlying)
Footnotes (2)
- [F1]Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025.
- [F2]Not applicable.
Documents
Issuer
Summit Therapeutics Inc.
CIK 0001599298
Entity typeother
Related Parties
1- filerCIK 0001507650
Filing Metadata
- Form type
- 4
- Filed
- Apr 30, 8:00 PM ET
- Accepted
- May 1, 6:03 PM ET
- Size
- 9.9 KB